



**Laura K. Shawver, Ph.D.**  
**SU2C Scientific Advisory Committee**



**Laura K. Shawver, Ph.D.**

President and CEO, Capstan Therapeutics  
Member, Stand Up To Cancer Scientific Advisory Committee  
San Diego, CA

**Laura K. Shawver, Ph.D.** is president and chief executive officer of Capstan Therapeutics, with a mission to multiply the therapeutic possibilities for patients by developing targeted in vivo RNA technologies. She received her doctorate in pharmacology at the University of Iowa in 1984 and did postdoctoral training at the University of Virginia Cancer Center and the department of hematology and oncology at Washington University.

Before joining Capstan, Shawver was president and CEO of Silverback Therapeutics, a company utilizing an ImmunoTAC™ platform which pairs antigen binding domains with disease pathway-modulating payloads to create innovative therapies for cancer, virology and fibrosis. She was also president and CEO of Synthorx, Inc utilizing synthetic biology to tune receptor pharmacology of cytokines and extend their half-life for immune-oncology and other serious diseases. Previously, she was CEO of Cleave Biosciences, Phenomix Corporation and president of SUGEN Inc. which focused on kinases and their function in cancer growth and survival. Her work in understanding the role of VEGF receptor in tumor angiogenesis led to the development of a new class of drugs including Sutent™ currently marketed by Pfizer for kidney and stomach cancer. Prior to her employment at SUGEN Inc., Shawver was employed at Berlex Biosciences (formerly Triton Biosciences). Diagnosed with ovarian cancer in 2006, she founded the non-profit organization, The Clarity Foundation which provides access to molecular profiling for women with recurrent and refractory disease to help prioritize treatment options. Shawver is an active member in the American Association for Cancer Research.